Researchers from the Cleveland Clinic and National Institutes of Health investigated the role of the neurobeachin (NBEA) gene in predicting weight loss response to glucagon-like peptide-1 receptor agonists.
In what represents the first PCT filing emerging in the name of Ayble Health Inc., protection is sought for a system for adaptive, multi-level processing of health data to be used in the individualized management of immune-mediated inflammatory diseases such as inflammatory bowel disease and irritable bowel syndrome.
TFF Pharmaceuticals Inc. has announced it is advancing into preclinical testing multivalent universal influenza vaccine candidates to protect against seasonal and pandemic viruses, in collaboration with Cleveland Clinic.
Theken Companies LLC reported the acquisition of Visionair Solutions Inc. from the Cleveland Clinic, a deal that adds pulmonary therapy to its broad portfolio with Visionair’s 3D platform for the creation of silicon stents for central airway obstructions (CAOs). Terms of the transaction, which has officially closed, were not disclosed.
Investigators from Foresee Pharmaceuticals Co. Ltd., Medical University of Vienna and Cleveland Clinic recently reported data on the effects of the matrix metalloproteinase-12 (MMP-12) inhibitor FP-020 in a mouse model of cardiac sarcoidosis in which chronic activation of mTORC1 signaling in myeloid cells causes spontaneous cardiac sarcoid-like granulomas.
In an age of overwhelming volumes of data that don’t fall together effortlessly into a lucid representation of reality, computational power is often the vital ingredient in leveraging existing data to push the frontiers of medicine. The Cleveland Clinic and IBM unveiled a quantum computing center that provides the sheer computational power needed to sort through the avalanche of data at a pace that will provide real insights into drug development and disease prediction, a development that portends truly revolutionary advances in disease prevention and treatment.
Pathogen-associated molecular patterns (PAMPs) are by themselves not enough to set off a full innate immune response to viral infection. Instead, structural changes to the actin cytoskeleton primed the activation of RIG-I-like receptors (RLRs), a family of intracellular RNA sensors that detect many types of viral RNA. When primed RLRs then encountered viral RNA, they set off an innate immune response that led to the production of interferons.
Pharmaceutical agents took center stage in Washington on the first full day of the 2022 scientific sessions of the American College of Cardiology, such as an April 2 presentation on the use of the mavacamten for obstructive hypertrophic cardiomyopathy (OHC). Milind Desai of the Cleveland Clinic said 16-week data for this cardiac myosin inhibitor showed well in reducing heart failure class status, but there are data arising from studies in China which suggest that radiofrequency (RF) ablation might also work for these patients.
Anixa Biosciences Inc. and the Moffitt Cancer Center now have details the FDA said it needs regarding their CAR T therapy development program. The collaborators said the information can be provided to the FDA in about 30 days. The agency then has 30 days to respond.
CLEVELAND – Patents took center stage on the final morning of Cleveland Clinic's Medical Innovation Summit, with two experts shedding some light on the issues surrounding patentability – particularly in light of recent legal cases and a hearing before a subcommittee of the Senate Judiciary Committee.
